Risk of Dengue Hospitalization in Monotypic and Multitypic Participants Aged 2–16 Years and Aged 9–16 Years (CYD14 + CYD15 Immunosubset)
| . | Annualized Risk of Dengue Hospitalizationb . | . | . | |||||
|---|---|---|---|---|---|---|---|---|
| . | Vaccine Group . | Placebo . | . | . | ||||
| Groupa . | no. . | No. . | Annual Incidence . | no. . | No. . | Annual Incidence . | Absolute Risk Reduction, % (95% CI) . | Relative Risk Reduction,c % (95% CI) . |
| Participants aged 2–16 y | ||||||||
| Monotypic | 9 | 481 | 0.3 | 19 | 251 | 1.3 | 0.95 (.37–1.53) | 75.3 (42.7–90.2) |
| Multitypic | 3 | 1183 | < 0.1 | 8 | 593 | 0.2 | 0.18 (.02–.34) | 81.2 (21.7–96.8) |
| Participants aged 9–16 y | ||||||||
| Monotypic | 5 | 338 | 0.2 | 11 | 169 | 1.1 | 0.84 (.18–1.50) | 77.3 (29.2–93.8) |
| Multitypic | 2 | 1042 | < 0.1 | 4 | 524 | 0.1 | 0.1 (−.04 to .23) | 74.8 (−75.5 to 97.7) |
| . | Annualized Risk of Dengue Hospitalizationb . | . | . | |||||
|---|---|---|---|---|---|---|---|---|
| . | Vaccine Group . | Placebo . | . | . | ||||
| Groupa . | no. . | No. . | Annual Incidence . | no. . | No. . | Annual Incidence . | Absolute Risk Reduction, % (95% CI) . | Relative Risk Reduction,c % (95% CI) . |
| Participants aged 2–16 y | ||||||||
| Monotypic | 9 | 481 | 0.3 | 19 | 251 | 1.3 | 0.95 (.37–1.53) | 75.3 (42.7–90.2) |
| Multitypic | 3 | 1183 | < 0.1 | 8 | 593 | 0.2 | 0.18 (.02–.34) | 81.2 (21.7–96.8) |
| Participants aged 9–16 y | ||||||||
| Monotypic | 5 | 338 | 0.2 | 11 | 169 | 1.1 | 0.84 (.18–1.50) | 77.3 (29.2–93.8) |
| Multitypic | 2 | 1042 | < 0.1 | 4 | 524 | 0.1 | 0.1 (−.04 to .23) | 74.8 (−75.5 to 97.7) |
Data are shown as number of participants (no.)/number of participants in full analysis set (No.) unless otherwise indicated.
Abbreviation: CI, confidence interval.
aMonotypic immune profile: participants with plaque reduction neutralization test (PRNT90) titers ≥ 10 (1/dilution) against only 1 dengue serotype at baseline. Multitypic immune profile: participants with PRNT90 titers ≥ 10 (1/dilution) against at least 2 dengue serotypes at baseline.
bThis was based on the cumulative risk over 6 years of follow-up.
cRelative risk reduction is equivalent to vaccine efficacy.
Risk of Dengue Hospitalization in Monotypic and Multitypic Participants Aged 2–16 Years and Aged 9–16 Years (CYD14 + CYD15 Immunosubset)
| . | Annualized Risk of Dengue Hospitalizationb . | . | . | |||||
|---|---|---|---|---|---|---|---|---|
| . | Vaccine Group . | Placebo . | . | . | ||||
| Groupa . | no. . | No. . | Annual Incidence . | no. . | No. . | Annual Incidence . | Absolute Risk Reduction, % (95% CI) . | Relative Risk Reduction,c % (95% CI) . |
| Participants aged 2–16 y | ||||||||
| Monotypic | 9 | 481 | 0.3 | 19 | 251 | 1.3 | 0.95 (.37–1.53) | 75.3 (42.7–90.2) |
| Multitypic | 3 | 1183 | < 0.1 | 8 | 593 | 0.2 | 0.18 (.02–.34) | 81.2 (21.7–96.8) |
| Participants aged 9–16 y | ||||||||
| Monotypic | 5 | 338 | 0.2 | 11 | 169 | 1.1 | 0.84 (.18–1.50) | 77.3 (29.2–93.8) |
| Multitypic | 2 | 1042 | < 0.1 | 4 | 524 | 0.1 | 0.1 (−.04 to .23) | 74.8 (−75.5 to 97.7) |
| . | Annualized Risk of Dengue Hospitalizationb . | . | . | |||||
|---|---|---|---|---|---|---|---|---|
| . | Vaccine Group . | Placebo . | . | . | ||||
| Groupa . | no. . | No. . | Annual Incidence . | no. . | No. . | Annual Incidence . | Absolute Risk Reduction, % (95% CI) . | Relative Risk Reduction,c % (95% CI) . |
| Participants aged 2–16 y | ||||||||
| Monotypic | 9 | 481 | 0.3 | 19 | 251 | 1.3 | 0.95 (.37–1.53) | 75.3 (42.7–90.2) |
| Multitypic | 3 | 1183 | < 0.1 | 8 | 593 | 0.2 | 0.18 (.02–.34) | 81.2 (21.7–96.8) |
| Participants aged 9–16 y | ||||||||
| Monotypic | 5 | 338 | 0.2 | 11 | 169 | 1.1 | 0.84 (.18–1.50) | 77.3 (29.2–93.8) |
| Multitypic | 2 | 1042 | < 0.1 | 4 | 524 | 0.1 | 0.1 (−.04 to .23) | 74.8 (−75.5 to 97.7) |
Data are shown as number of participants (no.)/number of participants in full analysis set (No.) unless otherwise indicated.
Abbreviation: CI, confidence interval.
aMonotypic immune profile: participants with plaque reduction neutralization test (PRNT90) titers ≥ 10 (1/dilution) against only 1 dengue serotype at baseline. Multitypic immune profile: participants with PRNT90 titers ≥ 10 (1/dilution) against at least 2 dengue serotypes at baseline.
bThis was based on the cumulative risk over 6 years of follow-up.
cRelative risk reduction is equivalent to vaccine efficacy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
